At the 2026 JPMorgan Healthcare Conference, Novo Nordisk’s CEO discussed the company’s pricing approach for its GLP-1 diabetes and obesity drugs, emphasizing sustainability amid global demand. Pfizer’s CEO also outlined a long-term expansion plan targeting the obesity therapeutics market.
- Novo Nordisk reported $12.8 billion in GLP-1 product revenue in Q4 2025, up 14% year-over-year.
- Wegovy’s average wholesale price exceeds $1,100 per month, with 38% of U.S. prescriptions covered by patient assistance programs.
- Pfizer’s PF-700 achieved a mean weight loss of 16.3% in Phase III trials, with FDA submission expected in Q2 2026.
- Novo Nordisk plans to launch an oral GLP-1 formulation in late 2026.
- Pfizer is partnering with a U.S. telehealth provider to enhance patient engagement for future obesity therapies.
- International GLP-1 sales grew 22% year-over-year in 2025, reflecting expanding market access.
Novo Nordisk’s CEO delivered a detailed update on the company’s pricing model for its flagship GLP-1 medications, including Wegovy and Ozempic, during a keynote session at the JPMorgan Healthcare Conference. The executive highlighted that while the company has maintained premium pricing—average wholesale prices for Wegovy exceed $1,100 per month—the strategy is designed to ensure long-term R&D investment and global supply stability. Despite inflationary pressures and calls for cost containment in several key markets, Novo Nordisk reported a 14% year-over-year increase in GLP-1 product revenue in Q4 2025, reaching $12.8 billion globally. The CEO stressed that pricing decisions are balanced against access, noting that patient assistance programs now cover 38% of prescriptions in the U.S. and expanded coverage in 12 emerging markets in 2025. These initiatives, combined with a 22% year-over-year increase in international sales, underscore the company’s dual focus on profitability and equitable access. The discussion comes as Novo Nordisk prepares to launch an oral formulation of its GLP-1 drug in late 2026, expected to drive additional market penetration. Meanwhile, Pfizer’s CEO presented a strategic roadmap for its obesity-focused pipeline, including the Phase III trial results for its investigational drug PF-700, which showed a mean weight loss of 16.3% over 52 weeks in obese adults. The company plans to file for FDA approval in Q2 2026, with commercial launch scheduled for late 2026. Pfizer also announced a partnership with a U.S.-based telehealth provider to integrate digital health tools with its future obesity therapies, aiming to improve adherence and long-term outcomes.